Healthcare news on October 29, 2026

1. 0100:00 UTC

   FDA alert on Medline beds prompts full market exit, refunds

   6 outlets · first: U.S. Food and Drug Administration (.gov) Medical devices

   Machine summary The FDA issued an Early Alert on Medline brand beds and accessories used in home and long-term care settings, citing fire risk from overheating electrical components and entrapment or asphyxiation risk from accessories. According to the company, at least two deaths, along with 16 injuries, had been linked to the products by Oct. 20; earlier in October, it announced plans to pull the beds from sale and leave that market.

   Reported by U.S. Food and Drug Administration (.gov), TradingView, Reuters, Seeking Alpha, Chicago Tribune and chicago.suntimes.com.

   • Food and Drug Administration
   • Early Alert
   • Medline brand beds and accessories

   Full coverage: every report, when each was published, and who was named (6 outlets)

2. 0218:57 UTC

   Judge blocks CMS Medicaid frailty rule for work requirement exemptions

   2 outlets · first: STAT News Regulation

   Machine summary U.S. District Judge Richard Stearns in Boston issued a 16-page ruling finding that CMS exceeded its authority when it required Medicaid beneficiaries with serious medical conditions to also show those conditions impair their ability to meet work requirements to qualify as medically frail. Twenty‑five states plus the District of Columbia formed a coalition that filed suit against the Trump administration in June, challenging guidance connected for 2025 One Big Beautiful Bill. The coalition argued that the rule would prevent eligible patients from receiving care. A federal judge halted the CMS Medicaid frailty rule that governs work‑requirement exemptions. The American Medical Association, which opposed the CMS guidance, said the ruling rightly rejected restrictions that would have raised barriers for people with serious or complex health conditions.

   1. U.S. District Judge Richard Stearns in Boston issued a 16-page ruling finding that CMS exceeded its authority by narrowing the medical-conditions exceptions to Medicaid work requirements, as reported by STAT News
   2. Under CMS guidance, individuals who are blind or disabled, who have substance use disorders or disabling mental disorders, or who have serious or complex medical conditions were also required to demonstrate that their condition impairs their capacity to comply with work requirements in order to qualify as medically frail.
   3. In June, 25 states plus the District of Columbia joined forces to sue the Trump administration over the guidance, tied to a 2025 law called the One Big Beautiful Bill.
   4. Stearns wrote that the states met their burden of showing irreparable harm, citing the costly and intensive alterations they would face to their eligibility verification systems
   5. Under the One Big Beautiful Bill, the definition of medically frail must encompass individuals who are blind or disabled, those with substance use disorders or disabling mental disorders, anyone whose disabilities markedly hinder daily tasks, and persons with serious or complex medical conditions.

   Reported by STAT News and MedPage Today.

   • Trump Administration
   • American Medical Association
   • One Big Beautiful Bill

3. 0321:27 UTC

   Coverage recordThe National Law Review: “FTC STAFF SEND WARNING LETTERS TO 25 HEALTHCARE PLAN MARKETERS AND LEAD GENERATORS”

   2 outlets · first: The National Law Review Regulation

   Reports ran from 21:27 UTC on Oct 29 to 01:17 UTC on Oct 30.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by The National Law Review and National Law Review.

   • FTC

4. 0417:44 UTC

   Omnicell narrows 2026 revenue view to $1.225B-$1.231B, lifts EBITDA goal

   2 outlets · first: Motley Fool Health IT

   Machine summary Omnicell reported $308 million in Q3 2026 revenue, which the earnings call transcript describes as a 1% year-over-year decrease, with service revenue of $135 million against $133 million a year earlier and product revenue of $173 million against $177 million. Management raised full-year non-GAAP EBITDA guidance to $187 million to $193 million from $175 million to $185 million and non-GAAP EPS guidance to $2.48 to $2.56. Year-end ARR guidance was narrowed to $660 million to $670 million, which the transcript attributes to timing visibility for growth in the consumables business.

   1. Omnicell reported Q3 2026 total revenue of $308 million, which the transcript describes as a 1% decrease year over year
   2. Q3 2026 non-GAAP EBITDA was $45 million, above the high end of prior management guidance, with cost efficiencies and customer mix cited
   3. Q3 2026 non-GAAP EPS was $0.58 versus a prior guidance range of $0.41 to $0.49; GAAP net income was $11 million, or $0.24 per diluted share, up from $5 million a year earlier
   4. Full-year 2026 non-GAAP EBITDA guidance was raised to $187 million to $193 million from $175 million to $185 million, and non-GAAP EPS guidance to $2.48 to $2.56 from $2.20 to $2.40
   5. For the full year 2026, the revenue outlook was narrowed to a range of $1.225 billion to $1.231 billion, while product bookings guidance was placed at $425 million to $560 million, a figure management said is weighted toward the fiscal year's end.

   Reported by Motley Fool and Seeking Alpha.

   • Omnicell
   • Annual recurring revenue (ARR)
   • Non-GAAP EBITDA

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.